The Obama administration announced Monday afternoon that the National Institutes of Health will redirect $100 million in funding to establish a new program to find better treatments--and eventually, a cure--for HIV and AIDS.
The government shutdown and subsequent furloughing of staff at the National Institutes of Health (NIH) has some obvious, headline-grabbing implications for its trials and research. Yet there are also a host of knock-on effects rippling through the private sector, harming bioinformatics and other fields.
Researchers at the National Institutes of Health have created genetically altered mice that outlive regular mice by about 20%--the equivalent of raising the average human lifespan by 16 years, from 79 to 95.
Chronic inflammation has long been thought to have ties to Type 2 diabetes, and now researchers at the National Institutes of Health believe they have discovered what that connection may be. The findings also point to a possible molecular target for treating the disease, which is a growing epidemic in the U.S.
Biomedical researchers will now be able to apply for access to the whole genome data of an important cell line known as HeLa.
In an effort to advance drug and disease research in children, a unit of the National Institutes of Health aims to fund studies of biomarkers of adult ailments for use in pediatric patients.
To effectively target cancer or autoimmune disease cells without causing too much harm to healthy ones in the process, researchers are turning to molecular "robots," small DNA-based platforms with binding sites highly specified to interact solely with disease-causing populations.
Researchers from the U.S. and China have developed statistical models that simulate a drug's reaction in a patient, an innovation that could help deliver treatments to specific disease targets.
The National Institutes of Health is all but closing the door on the use of chimps in drug research in the U.S., handing retirement papers out on more than 300 government-owned primates.
Sanofi research czar Elias Zerhouni has pushed for the company to delve deeply into the study of diseases before leaping into drug development. Now the French drug giant plans to collaborate with the software company NextBio to infuse patients' genomic and other data into its work on treatments for such diseases as cancer and diabetes.